Vaccines and Public Health: Nottingham & Nottinghamshire ICB

Developing a New Solution for Vaccination Delivery

Nottingham & Nottinghamshire Integrated Care Board

July 2025 – Present

Vaccine coverage rates for non-COVID programmes declined during the pandemic, highlighting health inequalities. The NHS Vaccination Strategy outlines measures to improve protection against vaccine-preventable diseases. This project, in collaboration with Nottingham & Nottinghamshire ICB, brings together stakeholders from primary care, community pharmacy, NHS Confederation, and MSD to address low vaccination uptake and redevelop immunisation services in the region.

Summary:

This 6 month project aims to identify a vaccine delivery solution that is responsive to local communities, provides effective local delivery, and addresses low uptake and accessibility of vaccinations in Nottingham and Nottinghamshire. Using NHS Confederation’s Five Step Process, the project will assess data to inform solutions. It focuses on Flu and Covid vaccinations in Nottingham City and Nottingham North, to include under 65s, pregnant women, at-risk individuals, and those with long-term conditions.

Objectives:

Identify lowest areas of Flu & Covid vaccine uptake
Understand barriers to access and uptake through community engagement
Co-develop a responsive and effective local delivery solution
Ensure equitable access to Flu & Covid vaccines

Service:

This project aims to use NHS Confederation’s Five-Step process: (i) address the inequalities in vaccine uptake; (ii) understand challenges in implementation of the NHS Vaccination Strategy; and (iii) to collaboratively develop sustainable solutions that will reduce vaccination and immunisation inequalities.

Get in touch

Talk to one of the team about challenges you’re facing and find out how we can help

Let’s talk

GB-NON-11826 | Date of Preparation: September 2025

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
GB-NON-11812 | Date of Preparation: September 2025